source
- Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanomaA Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…
- Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 dataBiogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…STAT · 4mo agoPositive readoutPositive